FDA Advisers Back Looser Rules For Six Peptides, Reject One (1) - Bloomberg Law News
High confidence: full text extraction produced 953 characters.
An FDA advisory committee advanced recommendations for six popular peptides to be legally compounded and sold by pharmacies, rejecting only one substance for looser manufacturing restrictions championed by US Health Secretary Robert F. Kennedy Jr.
The agencyâs outside advisers sitting on the Pharmacy Compounding Advisory Committee on Friday only declined to reclassify the peptide Emideltide as a substance that pharmacies would be allowed to legally market. The unapproved product is being evaluated for its use for opioid withdrawal and insomnia.
However, in votes Thursday and Friday, the majority of the committee agreed to recommend the unapproved peptides for compounding: Epitalon ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.